Cargando…

Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia

T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative th...

Descripción completa

Detalles Bibliográficos
Autores principales: Varadarajan, Indumathy, Ballen, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873924/
https://www.ncbi.nlm.nih.gov/pubmed/35223471
http://dx.doi.org/10.3389/fonc.2022.781479
_version_ 1784657569418051584
author Varadarajan, Indumathy
Ballen, Karen
author_facet Varadarajan, Indumathy
Ballen, Karen
author_sort Varadarajan, Indumathy
collection PubMed
description T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative therapy in eligible patients. However, allogeneic stem cell transplant is also complicated by increased rates of infections from chemotherapy, acute graft-versus-host disease (GVHD), and chronic GVHD. This review aims to report the available literature on the efficacy and complications of consolidative HSCT. It also discusses the importance of patient selection and pre- and post-transplant complications including atypical infections and GVHD.
format Online
Article
Text
id pubmed-8873924
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88739242022-02-26 Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia Varadarajan, Indumathy Ballen, Karen Front Oncol Oncology T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative therapy in eligible patients. However, allogeneic stem cell transplant is also complicated by increased rates of infections from chemotherapy, acute graft-versus-host disease (GVHD), and chronic GVHD. This review aims to report the available literature on the efficacy and complications of consolidative HSCT. It also discusses the importance of patient selection and pre- and post-transplant complications including atypical infections and GVHD. Frontiers Media S.A. 2022-02-11 /pmc/articles/PMC8873924/ /pubmed/35223471 http://dx.doi.org/10.3389/fonc.2022.781479 Text en Copyright © 2022 Varadarajan and Ballen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Varadarajan, Indumathy
Ballen, Karen
Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
title Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
title_full Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
title_fullStr Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
title_full_unstemmed Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
title_short Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
title_sort advances in cellular therapy for t-cell prolymphocytic leukemia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873924/
https://www.ncbi.nlm.nih.gov/pubmed/35223471
http://dx.doi.org/10.3389/fonc.2022.781479
work_keys_str_mv AT varadarajanindumathy advancesincellulartherapyfortcellprolymphocyticleukemia
AT ballenkaren advancesincellulartherapyfortcellprolymphocyticleukemia